1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-06-24 am EDT
3570.00 JPY   +2.79%
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemophilia A
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes

04/26/2022 | 09:24am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the following organizational and personnel changes, effective July 1, 2022.

[Details of Organizational Changes]

1. Reorganization of Pharmaceutical Technology Div.

Pharmaceutical Technology Div. currently has two functions: the R&D function for pharmaceutical technology (PT) including technical research, and the manufacturing function to supply high-quality investigational drugs and products in a stable and efficient manner, in cooperation with a manufacturing subsidiary Chugai Pharma Manufacturing Co., Ltd. (CPMC). Two separate divisions will be in place to further enhance these functions which play a key role in realizing TOP I 2030.

Pharmaceutical Technology Div. will be divided into Pharmaceutical Technology Div., which is centered on the PT R&D function, and Manufacturing Technology Div., which is centered on the manufacturing function. Related departments will be also reorganized.

Pharmaceutical Technology Div. will include PT Planning & Coordination Dept., CMC Regulatory Affairs Dept., API Process Development Dept., Formulation Development Dept., and Analytical Development Dept. Manufacturing Technology Div. will consist of Supply Chain Management Dept., Quality Management Dept. and CPMC.

Reorganization of Marketing & Sales Div.

In order to further strengthen the expertise and to concentrate on growth and new areas, the region-based sales organization will be changed into a disease area-based system focusing on the two diseases areas of oncology and specialty diseases, considering the changes in the healthcare industry and the Company's portfolio of products and projects under development. The 36 sales branches in Japan will also be reorganized into 33 branches. Back office operations in regional management offices will be consolidated and centralized to enable efficient and fast collaboration with related organizations.

Hokkaido & Tohoku Regional Management Office will be renamed Kita-Nihon Regional Management Office

Oncology Marketing & Sales Promotion Dept. and Primary Marketing & Sales Promotion Dept. will be renamed Oncology Marketing Dept. and Specialty Marketing Dept., respectively.

3. Other renames

Considering the portfolio of products and projects under development, 'Primary' used in the names of organizations will be replaced with 'Specialty.'

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD 2.79% 3570 Delayed Quote.-4.42%
ROCHE HOLDING AG 4.08% 318.8 Delayed Quote.-15.91%
All news about CHUGAI PHARMACEUTICAL CO., LTD
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo..
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemop..
MT
06/20Roche's Chugai, Zenyaku Kogyo Win Japanese Nod For Rituxan Drug Against Neuromyelitis O..
MT
06/20Roche's Chugai Pharmaceutical Wins Japanese Regulatory Nod For Changes To Leukemia, Ova..
MT
06/20CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Hemlibra for Additional Indication..
PU
06/20CHUGAI PHARMACEUTICAL : Obtains Partial Change Approval for Neutrogin and Avastin Based on..
PU
06/20CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention ..
PU
06/10Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pa..
MT
06/10Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Ni..
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 185 B 8 774 M 8 774 M
Net income 2022 342 B 2 529 M 2 529 M
Net cash 2022 571 B 4 225 M 4 225 M
P/E ratio 2022 17,2x
Yield 2022 2,18%
Capitalization 5 871 B 43 454 M 43 454 M
EV / Sales 2022 4,47x
EV / Sales 2023 4,95x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 570,00 JPY
Average target price 4 639,23 JPY
Spread / Average Target 30,0%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-4.42%43 454
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202